DS process characterization

Ended Awarded Last action

Contract number
W911SR22F0073
Awardee
Awarding agency
Obligated
$4,459,366

Award facts

Opportunity
  • W911SR22R0040 Solicitation number
Contract value 92% obligated
  • $4,459,366.48 Current, with exercised options
  • $4,861,155.86 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Funding agency
Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
Set-aside
No set-aside
Competition
Not Available for Competition Only One Source
Pricing
Cost Plus Fixed Fee
Place of performance
Santa Fe, FL 32615, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Terminate for Default P00010 $0
Funding Only Action P00009 -$26,789
Other Administrative Action P00008 $0
Funding Only Action P00007 -$375,000
Funding Only Action P00006 · This delivery order is for research and development tasks associated with developing a US food and drug administration licensed monoclonal antibody… $0
Supplemental Agreement for work within scope P00005 · U.S. Food and drug administration (FDA) licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure contract effort. $999,909
Other Administrative Action P00004 $1,100,000
Other Administrative Action P00003 -$1,656,275
Supplemental Agreement for work within scope P00002 $2,000,000
Supplemental Agreement for work within scope P00001 $0
Original award $2,417,522
Show all 11

About this award

Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) was awarded a $4.86 million delivery order by the Department of Defense's Joint Program Executive Office for Chemical and Biological Defense to conduct research and development activities for a monoclonal antibody countermeasure against botulinum neurotoxin. The contract is structured as a cost-plus-fixed-fee delivery order with work to be performed in Alachua, Florida, and is scheduled for completion by February 28, 2025. The award was issued on June 16, 2022, with no set-aside designation applied.

This delivery order represents a component of Resilience's broader engagement with the Department of Defense on medical countermeasure development. The contractor currently holds a $249 million single-award Indefinite Delivery Contract with the Army Acquisition Support Center that serves as the primary acquisition vehicle for FDA-approved products supporting chemical and biological defense initiatives. Resilience specializes in biomanufacturing and process development for complex medicines, with demonstrated experience advancing countermeasures through clinical trials and regulatory approval processes aimed at achieving FDA licensure for biological threat mitigation.

Quick answers

Who was awarded contract W911SR22F0073?

W911SR22F0073 was awarded to Resilience Government Services, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on June 16, 2022.

How much is contract W911SR22F0073 worth?

The government has obligated $4,459,366 on W911SR22F0073. Its potential value, with all options, is $4,861,156.

Which agency awarded contract W911SR22F0073?

ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR22F0073, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).

Is contract W911SR22F0073 an order under another contract?

Yes. W911SR22F0073 is a delivery order under W911SR22D0009, an indefinite delivery contract.

Was contract W911SR22F0073 competed?

The extent of competition for W911SR22F0073 was not available for competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award